[Spontaneous resolution of ATRA-related hearing impairment without symptoms of intracranial hypertension].

All-trans retinoic acid (ATRA) is essential in treating acute promyelocytic leukemia (APL), but has been linked to adverse events such as differentiation syndrome and intracranial hypertension. Hearing impairment associated with intracranial hypertension is rare but clinically relevant. We report the case of a 6-year-old girl with APL who developed transient low-frequency sensorineural hearing impairment during ATRA/arsenic trioxide therapy. No headache or neurologic signs suggesting intracranial hypertension were observed, and both hearing symptoms and low-frequency audiometric changes resolved spontaneously without corticosteroids or treatment modification. This case suggests that ATRA-related hearing impairment may occur even without intracranial hypertension, and careful monitoring may enable continuation of therapy.